Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
Tuebingen, Germany and Houston, TX, July 24, 2023 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in...
Month: July 2023
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for multiple myeloma
Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for...
Eagle Pharmaceuticals Announces First Patient Randomized in Phase 2 Study Evaluating CAL02, a Novel First-in-Class Anti-Toxin Drug Candidate, in Severe Community-Acquired Bacterial Pneumonia (SCABP)
Despite the availability of antibiotics, the death rate from pneumonia in the U.S. has seen little improvement in the past...
BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023
MAINZ, Germany, July 24, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial...
Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023
Company to hold investor conference call on Monday, July 31, 2023 at 1:30 p.m. PT / 4:30 p.m. ETBRISBANE, Calif.,...
Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in patients with Stargardt Disease (STGD1)...
International Self-Care Day: Better Self-Care, Better Healthcare; Better Welfare Globally
Continued calls for WHO resolution on self-careNYON, SWITZERLAND / ACCESSWIRE / July 24, 2023 / International Self-Care month 2023 opened...
Bavarian Nordic Provides Update on RSV Vaccine Program
Phase 3 study failed to meet one of the success criteria of the primary objectiveRSV program to be discontinuedCOPENHAGEN, Denmark,...
The Assistance Fund Opens New Program for Small Cell Lung Cancer
Financial Assistance From The Assistance Fund Now Available for Eligible People Living With Small Cell Lung CancerORLANDO, FL / ACCESSWIRE...
Achieve Your Dream Smile: Unbeatable Veneers in Colombia at VeneersColombia.com
MEDELLÍN, COLOMBIA, ANTIOQUIA / ACCESSWIRE / July 22, 2023 / Situated in Medellin's prestigious "El Poblado," VeneersColombia.com stands out as...
Cosmos Health Inc. Announces Closing of $5.25 Million Registered Direct Offering and Concurrent Private Placement
CHICAGO, IL / ACCESSWIRE / July 21, 2023 / Cosmos Health Inc. (the "Company") (Nasdaq:COSM), a global healthcare group with...
Allied OMS Announces Appointment of Dr. Jonathon Jundt as Chief Medical Officer
SOUTHLAKE, TX / ACCESSWIRE / July 21, 2023 / Allied OMS - the country's only doctor-owned, doctor-led, and doctor-governed management...
Best’s Special Report: Unprofitable Auto, Property Insurance Results Weaken Property/Casualty Industry’s 2022 Underwriting Performance
OLDWICK, N.J.--(BUSINESS WIRE)--#insurance--Significant deterioration in the U.S. personal lines segment’s underwriting results, particularly in the private passenger auto line of...
Biotricity Regains Nasdaq Listing Compliance
REDWOOD CITY, CA / ACCESSWIRE / July 21, 2023 / Biotricity, Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the...
BioRestorative Therapies (NASDAQ:BRTX) Receives Landmark License From New York State
MELVILLE, NY / ACCESSWIRE / July 21, 2023 / BioRestorative Therapies Inc. (NASDAQ:BRTX) ("BioRestorative"), a clinical-stage company specializing in stem...
Correction: Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
Positive opinion from Committee for Medicinal Products for Human Use (CHMP) based on Bylvay Phase III ASSERT clinical-trial data in...
Janssen Receives Positive CHMP Opinions for Novel Bispecific Antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Talquetamab is the first therapy targeting GPRC5D to receive a positive CHMP Opinion Teclistamab, the first BCMA-targeting bispecific antibody to...
Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix
Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder valueBOULDER, Colo., July 21, 2023 (GLOBE NEWSWIRE)...
Genetic Technologies Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
MELBOURNE, Australia, July 21, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests...
Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
Positive opinion from Committee for Medicinal Products for Human Use (CHMP) based on Bylvay Phase III ASSERT clinical-trial data in...